Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 3
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 3(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00375388Phase 3Completed

The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial

Role: collaborator

NCT00002225Phase 2Completed

A Study of Efavirenz in Combination With Stavudine and Didanosine

Role: lead

NCT00002227Phase 2Completed

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Role: lead

NCT00002393Phase 3Completed

A Study of Indinavir Taken With or Without DMP 266

Role: lead

NCT00002410Phase 3Completed

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Role: lead

All 5 trials loaded